Antibodies that block siglec can act as antagonists by obstructing ligand binding. Natural killer cell activity toward Siglec-7 and Siglec-9 may be a significant factor in determining tumor engraftment because these cells have been shown to have a function in the early stages of carcinogenesis. Researchers have discovered Siglec-15 through an array, which is primarily detected on tumor cells and macrophages associated with tumors and has little expression in normal tissues. It was discovered that such ablation boosts the anti-tumor immune responses using Siglec-15 knockout animals and a blocking antibody against Siglec-15.
CD BioGlyco provides Glycobiology Microarray Platforms such as Lectin Microarray Assay for customers to help them research blocking antibody-targeted Siglecs.
Fig.1 Approaches to target Siglec–Sia axis. (Läubli, et al., 2020)
It has been possible to understand how NK cell-mediated cytotoxicity affects cancer cell lines by using the anti-Siglec-7 clon. Siglec-7 inhibiting antibody therapy has improved the death of cancer cells. Another clone of the Siglec-7 antibody was utilized to block Siglec-7 from interacting with sialoglycan-decorated Jurkat cells.
The cytotoxicity of NK cells on cancer cell lines was examined using the anti-Siglec-9 Fab fragments. Although the cytotoxicity was shown to be increased, the effects were not as strong as those from Siglec-7-blocking.
Anti-Siglec-10 was utilized as a blocking antibody to suppress the CD24-Siglec-10 axis, and it significantly increased the ability of macrophages to phagocytose tumor cells. Furthermore, the CD24-blocking antibody produced the same phenotype, supporting the connection between Siglec-10 expressed by TAMs and CD24 expressed by tumors.
Using the hybridoma technique, a blocking antibody for Siglec-15 was produced. It has been demonstrated that blocking antibody therapy lowers the established tumor's burden.
Immune checkpoints are often in charge of stopping uncontrolled immune responses to guarantee little collateral cell harm. However, these immunological checkpoints on immune cells can be activated by cancer cells to make them inert or anergic, assuring their own survival and expansion. Therefore, using immune checkpoint inhibitors, such as monoclonal antibodies (mAbs), with the potential to disrupt the immuno-regulatory interactions between tumors and immune cells, is a key component of cancer immunotherapy. Siglec-9 is one of the Siglecs and is expressed on myeloid cells, NK cells, and a subset of T cells. Siglec-9 can bind to sialoglycans and impair the immune system's ability to fight tumors. For instance, Siglec-9 expression on NK cells can suppress the body's ability to fight tumors. Having access to very targeted anti-Siglec-9 antibodies is essential for the possible immunotherapy strategy to be successful. Customers can find Glycoengineered Antibody-based Glycomedicine Development to study applications of Siglecs-blocking antibodies.
CD BioGlyco has a outstanding antibody-based glycomedicine development platform and provides customized services according to research needs. if you are interested in our services, please feel free to contact us for more detailed information.
Reference:
